Investment Analysts’ Weekly Ratings Updates for NeoGenomics (NEO)

A number of firms have modified their ratings and price targets on shares of NeoGenomics (NASDAQ: NEO) recently:

• 3/3/2023 – NeoGenomics had its price target raised by analysts at Piper Sandler from $18.00 to $20.00. They now have an “overweight” rating on the stock.
• 2/25/2023 – NeoGenomics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 2/24/2023 – NeoGenomics had its price target raised by analysts at Raymond James from $12.00 to $19.00. They now have an “outperform” rating on the stock.
• 2/24/2023 – NeoGenomics had its price target raised by analysts at Cowen Inc from $14.00 to $20.00. They now have an “outperform” rating on the stock.
• 2/24/2023 – NeoGenomics had its price target raised by analysts at Morgan Stanley from $17.00 to $18.00. They now have an “equal weight” rating on the stock.
• 2/24/2023 – NeoGenomics had its price target raised by analysts at Needham & Company LLC from $15.00 to $21.00. They now have a “buy” rating on the stock.
• 2/24/2023 – NeoGenomics was upgraded by analysts at Benchmark Co. from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock.
• 2/17/2023 – NeoGenomics was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 2/9/2023 – NeoGenomics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 2/1/2023 – NeoGenomics was upgraded by analysts at Needham & Company LLC from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock.

NeoGenomics Price Performance

Shares of NEO stock opened at $17.51 on Tuesday. NeoGenomics, Inc. has a 52-week low of $6.00 and a 52-week high of $19.93. The stock has a market cap of $2.23 billion, a PE ratio of -15.09 and a beta of 1.13. The company has a debt-to-equity ratio of 0.54, a quick ratio of 6.46 and a current ratio of 6.73. The firm’s 50 day moving average price is $12.26 and its two-hundred day moving average price is $10.50.

Hedge Funds Weigh In On NeoGenomics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in NeoGenomics by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 12,970,503 shares of the medical research company’s stock valued at $157,592,000 after acquiring an additional 113,534 shares in the last quarter. Brown Advisory Inc. lifted its position in NeoGenomics by 3.6% in the 4th quarter. Brown Advisory Inc. now owns 6,403,985 shares of the medical research company’s stock valued at $59,173,000 after acquiring an additional 223,250 shares in the last quarter. State Street Corp lifted its position in NeoGenomics by 2.8% in the 3rd quarter. State Street Corp now owns 4,217,160 shares of the medical research company’s stock valued at $36,310,000 after acquiring an additional 116,802 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in NeoGenomics by 13.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,916,935 shares of the medical research company’s stock valued at $26,953,000 after acquiring an additional 348,026 shares in the last quarter. Finally, First Light Asset Management LLC lifted its position in NeoGenomics by 236.9% in the 2nd quarter. First Light Asset Management LLC now owns 2,715,487 shares of the medical research company’s stock valued at $22,131,000 after acquiring an additional 1,909,529 shares in the last quarter. 88.15% of the stock is owned by institutional investors.

NeoGenomics, Inc is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups.